Tag Archives | Stuart McCully

eConsent

Transcelerate eConsent Initiative

While the shift to digital technologies is pervasive across multiple industries, the informed consent process for clinical trials has been historically paper-based.  Given the inefficiencies in the traditional process and the increasing complexity of clinical studies, the current approach at times may raise challenges with respect to quality, compliance, patient understanding and trial retention. The […]

Continue Reading
Germany-map-colour

German RECs Seek to Simplify NIS Approval

Germany – Professional Advice under Section 15 BO Ärzte: Speeding up the Process for Non-Interventional Studies? Author: Mark Heinemann, Principal Regulatory Advisor, CHCUK Consulting German Ethics Committees (ECs) make an important step towards the simplification of the ethical evaluation of Non-Interventional Studies (NIS). A number of University and State Medical Association Ethics Committees take part […]

Continue Reading
Digital-Medicine

Trump Administration Announces MyHealthEData Initiative at HIMSS18

The Trump Administration is launching the MyHealthEData initiative which aims to empower patients by ensuring that they control their healthcare data and can decide how their data is going to be used, all while keeping that information safe and secure CMS is committed to putting patients first, and that’s why we approach issues with healthcare […]

Continue Reading
CombinationProduct

FDA – Postmarketing Safety Reporting for Combination Products

This DRAFT guidance addresses how to comply with the final rule on postmarketing safety  reporting (PMSR) requirements for combination products that FDA issued on December 20, 2016 (81 FR 92603, hereafter the “combination product PMSR final rule,” “final rule,” or “rule”).  The rule describes how to comply with PMSR requirements for combination products that have […]

Continue Reading
mhra_regulating_logo_strapline_rgb_screen

MHRA – Guidance on GxP Data Integrity

The way regulatory data is generated has continued to evolve in line with the ongoing development of supporting technologies such as the increasing use of electronic data capture, automation of systems and use of remote technologies; and the increased complexity of supply chains and ways of working, for example, via third party service providers. Systems […]

Continue Reading
RWLP-Regulatory-Database

Non-Interventional Studies – What is the Biggest Challenge?

Non-Interventional Studies… Q. What is the Biggest Challenge? A. Working out the regulatory requirements for your study! Finding out what’s needed to run a non-interventional study shouldn’t be difficult, but it is! We’ve taken the pain out of that process by collecting the relevant information per country and per study type and captured this in […]

Continue Reading

New FDA Guidance on Informed Consent Waiver for Clinical Investigations Involving No More than Minimal Risk

FDA issues guidance for immediate implementation- IRB Waiver or Alteration of Informed Consent for Clinical Investigations Involving No More Than Minimal Risk to Human Subjects Author: Patricia Garcia, Regulatory Consultant, Late Stage, Clinical Division, Inventiv Health Clinical Spain S.L. In July 2017, FDA issued this guidance for immediate implementation. Link to the Guidance: https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM566948.pdf The […]

Continue Reading